Brian Bigger - Search Results

Year	Number of Results
2003	1
2004	2
2005	3
2006	3
2007	2
2009	3
2010	6
2011	4
2012	8
2013	10
2014	7
2015	6
2016	2
2017	3
2018	10
2019	10
2020	5
2021	4
2022	4
2023	8
2024	5

1

Secondary deficiency of neuraminidase 1 contributes to CNS pathology in neurological mucopolysaccharidoses via hypersialylation of brain glycoproteins.

Xu T, Heon-Roberts R, Moore T, Dubot P, Pan X, Guo T, Cairo CW, Holley R, Bigger B, Durcan TM, Levade T, Ausseil J, Amilhon B, Gorelik A, Nagar B, Sturiale L, Palmigiano A, Röckle I, Thiesler H, Hildebrandt H, Garozzo D, Pshezhetsky AV. Xu T, et al. Among authors: bigger b. bioRxiv [Preprint]. 2024 Apr 27:2024.04.26.587986. doi: 10.1101/2024.04.26.587986. bioRxiv. 2024. PMID: 38712143 Free PMC article. Preprint.

2

Improving newborn screening test performance for metachromatic leukodystrophy: Recommendation from a pre-pilot study that identified a late-infantile case for treatment.

Wu THY, Brown HA, Church HJ, Kershaw CJ, Hutton R, Egerton C, Cooper J, Tylee K, Cohen RN, Gokhale D, Ram D, Morton G, Henderson M, Bigger BW, Jones SA. Wu THY, et al. Among authors: bigger bw. Mol Genet Metab. 2024 May;142(1):108349. doi: 10.1016/j.ymgme.2024.108349. Epub 2024 Feb 20. Mol Genet Metab. 2024. PMID: 38458124 Free article.

3

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture.

Suleman S, Fawaz S, Roberts T, Ellison S, Bigger B, Themis M. Suleman S, et al. Among authors: bigger b. J Virol Methods. 2024 Apr;325:114884. doi: 10.1016/j.jviromet.2024.114884. Epub 2024 Jan 11. J Virol Methods. 2024. PMID: 38218417 Free article.

4

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565.

Wiesinger AM, Bigger B, Giugliani R, Lampe C, Scarpa M, Moser T, Kampmann C, Zimmermann G, Lagler FB. Wiesinger AM, et al. Among authors: bigger b. Pharmaceutics. 2023 Nov 7;15(11):2596. doi: 10.3390/pharmaceutics15112596. Pharmaceutics. 2023. PMID: 38004626 Free PMC article.

5

Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy.

Ellison S, Liao A, Gleitz HFE, Parker H, Booth L, Robinson J, Wood S, Taylor J, Holley R, Bigger BW. Ellison S, et al. Among authors: bigger bw. Mol Ther Methods Clin Dev. 2023 Oct 20;31:101127. doi: 10.1016/j.omtm.2023.101127. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 37920237 Free PMC article.

6

Phenotypic characterisation of the Mucopolysaccharidosis Type I (MPSI) Idua-W392X mouse model reveals increased anxiety-related traits in female mice.

Andreou T, Ishikawa-Learmonth Y, Bigger BW. Andreou T, et al. Among authors: bigger bw. Mol Genet Metab. 2023 Aug;139(4):107651. doi: 10.1016/j.ymgme.2023.107651. Epub 2023 Jul 13. Mol Genet Metab. 2023. PMID: 37473537 Free article.

7

Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease.

Mandolfo O, Liao A, Singh E, O'leary C, Holley RJ, Bigger BW. Mandolfo O, et al. Among authors: bigger bw. Hum Gene Ther. 2024 Apr;35(7-8):243-255. doi: 10.1089/hum.2023.002. Epub 2023 Aug 30. Hum Gene Ther. 2024. PMID: 37427450

8

Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC.

O'Leary C, Forte G, Mitchell NL, Youshani AS, Dyer A, Wellby MP, Russell KN, Murray SJ, Jolinon N, Jones SA, Stacey K, Davis DM, Henckaerts E, Palmer DN, Kamaly-Asl I, Bigger BW. O'Leary C, et al. Among authors: bigger bw. J Transl Med. 2023 Jul 5;21(1):437. doi: 10.1186/s12967-023-04208-1. J Transl Med. 2023. PMID: 37407981 Free PMC article.

9

An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis.

Wiesinger AM, Bigger B, Giugliani R, Lampe C, Scarpa M, Moser T, Kampmann C, Zimmermann G, Lagler FB. Wiesinger AM, et al. Among authors: bigger b. Pharmaceutics. 2023 May 22;15(5):1565. doi: 10.3390/pharmaceutics15051565. Pharmaceutics. 2023. PMID: 37242808 Free PMC article. Retracted.

10

Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.

Wood SR, Chaudrhy A, Ellison S, Searle R, Burgod C, Tehseen G, Forte G, O'Leary C, Gleitz H, Liao A, Cook J, Holley R, Bigger BW. Wood SR, et al. Among authors: bigger bw. Hum Gene Ther. 2024 Apr;35(7-8):232-242. doi: 10.1089/hum.2023.025. Epub 2023 Jul 7. Hum Gene Ther. 2024. PMID: 37212263

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

87 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year